FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381197860> ?p ?o ?g. }

• W4381197860 endingPage "242" @default.
• W4381197860 startingPage "234" @default.
• W4381197860 abstract "Familial hypercholesterolaemia (FH) is a common hereditary genetic disorder, characterized by elevated circulating low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] concentrations, leading to atherosclerotic cardiovascular disease (ASCVD). Two types of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors- alirocumab and evolocumab- are efficient drugs in the treatment of FH, which can effectively reduce Lp(a) levels.Embase, MEDLINE, and PubMed up to November 2022 were searched for randomized clinical trials (RCTs) evaluating the effect of alirocumab/evolocumab and placebo treatment on plasma Lp(a) levels in FH. Statistics were analysed by Review Manager (RevMan 5.3) and Stata 15.1.Eleven RCTs involved a total of 2408 participants. Alirocumab/evolocumab showed a significant efficacy in reducing Lp(a) [weighted mean difference (WMD): -20.10%, 95% confidence interval (CI): -25.59% to -14.61%] compared with placebo. In the drug type subgroup analyses, although the efficacy of evolocumab was slightly low (WMD: -19.98%, 95% CI: -25.23% to -14.73%), there was no difference with alirocumab (WMD: -20.54%, 95% CI: -30.07% to -11.02%). In the treatment duration subgroup analyses, the efficacy of the 12-week duration group (WMD: -17.61%, 95% CI: -23.84% to -11.38%) was lower than in the group of ≥ 24 weeks' duration (WMD: -22.81%, 95% CI: -31.56% to -14.07%). In the participants' characteristics subgroup analyses, the results showed that no differential effect of alirocumab/evolocumab therapy on plasma Lp(a) concentrations was observed (heterozygous FH [HeFH] WMD: -20.07%, 95% CI: -26.07% to -14.08%; homozygous FH [HoFH] WMD: -20.04%, 95% CI: -36.31% to -3.77%). Evaluation of all-cause adverse events (AEs) between alirocumab/evolocumab groups and placebo groups [relative risk (RR): 1.05, 95% CI: 0.98-1.12] implied no obvious difference between the 2 groups.Anti-PCSK9 drugs (alirocumab and evolocumab) may be effective as therapy for reducing serum Lp(a) levels in FH, and no differences were observed in treatment durations, participant characteristics, and other aspects of the 2 types of PCSk9 inhibitors. However, further experimental studies and RCTs are warranted to clarify the mechanism of PSCK9 inhibitors to lowering Lp(a) concentrations in FH." @default.
• W4381197860 created "2023-06-20" @default.
• W4381197860 creator A5006094386 @default.
• W4381197860 creator A5021541475 @default.
• W4381197860 creator A5052274720 @default.
• W4381197860 creator A5056496709 @default.
• W4381197860 creator A5060210036 @default.
• W4381197860 creator A5062619262 @default.
• W4381197860 creator A5070595272 @default.
• W4381197860 creator A5075951772 @default.
• W4381197860 creator A5078587976 @default.
• W4381197860 date "2023-06-26" @default.
• W4381197860 modified "2023-10-04" @default.
• W4381197860 title "Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials" @default.
• W4381197860 doi "https://doi.org/10.5603/ep.a2023.0036" @default.
• W4381197860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37335067" @default.
• W4381197860 hasPublicationYear "2023" @default.
• W4381197860 type Work @default.
• W4381197860 citedByCount "0" @default.
• W4381197860 crossrefType "journal-article" @default.
• W4381197860 hasAuthorship W4381197860A5006094386 @default.
• W4381197860 hasAuthorship W4381197860A5021541475 @default.
• W4381197860 hasAuthorship W4381197860A5052274720 @default.
• W4381197860 hasAuthorship W4381197860A5056496709 @default.
• W4381197860 hasAuthorship W4381197860A5060210036 @default.
• W4381197860 hasAuthorship W4381197860A5062619262 @default.
• W4381197860 hasAuthorship W4381197860A5070595272 @default.
• W4381197860 hasAuthorship W4381197860A5075951772 @default.
• W4381197860 hasAuthorship W4381197860A5078587976 @default.
• W4381197860 hasBestOaLocation W43811978601 @default.
• W4381197860 hasConcept C126322002 @default.
• W4381197860 hasConcept C142724271 @default.
• W4381197860 hasConcept C168563851 @default.
• W4381197860 hasConcept C187960798 @default.
• W4381197860 hasConcept C204787440 @default.
• W4381197860 hasConcept C27081682 @default.
• W4381197860 hasConcept C2776104379 @default.
• W4381197860 hasConcept C2776478404 @default.
• W4381197860 hasConcept C2778114629 @default.
• W4381197860 hasConcept C2778163477 @default.
• W4381197860 hasConcept C2780072125 @default.
• W4381197860 hasConcept C2780745583 @default.
• W4381197860 hasConcept C2780902209 @default.
• W4381197860 hasConcept C2780948078 @default.
• W4381197860 hasConcept C43554185 @default.
• W4381197860 hasConcept C44249647 @default.
• W4381197860 hasConcept C71924100 @default.
• W4381197860 hasConcept C90924648 @default.
• W4381197860 hasConcept C95190672 @default.
• W4381197860 hasConceptScore W4381197860C126322002 @default.
• W4381197860 hasConceptScore W4381197860C142724271 @default.
• W4381197860 hasConceptScore W4381197860C168563851 @default.
• W4381197860 hasConceptScore W4381197860C187960798 @default.
• W4381197860 hasConceptScore W4381197860C204787440 @default.
• W4381197860 hasConceptScore W4381197860C27081682 @default.
• W4381197860 hasConceptScore W4381197860C2776104379 @default.
• W4381197860 hasConceptScore W4381197860C2776478404 @default.
• W4381197860 hasConceptScore W4381197860C2778114629 @default.
• W4381197860 hasConceptScore W4381197860C2778163477 @default.
• W4381197860 hasConceptScore W4381197860C2780072125 @default.
• W4381197860 hasConceptScore W4381197860C2780745583 @default.
• W4381197860 hasConceptScore W4381197860C2780902209 @default.
• W4381197860 hasConceptScore W4381197860C2780948078 @default.
• W4381197860 hasConceptScore W4381197860C43554185 @default.
• W4381197860 hasConceptScore W4381197860C44249647 @default.
• W4381197860 hasConceptScore W4381197860C71924100 @default.
• W4381197860 hasConceptScore W4381197860C90924648 @default.
• W4381197860 hasConceptScore W4381197860C95190672 @default.
• W4381197860 hasIssue "3" @default.
• W4381197860 hasLocation W43811978601 @default.
• W4381197860 hasLocation W43811978602 @default.
• W4381197860 hasOpenAccess W4381197860 @default.
• W4381197860 hasPrimaryLocation W43811978601 @default.
• W4381197860 hasRelatedWork W161816689 @default.
• W4381197860 hasRelatedWork W2892377448 @default.
• W4381197860 hasRelatedWork W3014821231 @default.
• W4381197860 hasRelatedWork W3026029514 @default.
• W4381197860 hasRelatedWork W3092976149 @default.
• W4381197860 hasRelatedWork W3106875627 @default.
• W4381197860 hasRelatedWork W3158680612 @default.
• W4381197860 hasRelatedWork W4280606105 @default.
• W4381197860 hasRelatedWork W4381197860 @default.
• W4381197860 hasRelatedWork W98619866 @default.
• W4381197860 hasVolume "74" @default.
• W4381197860 isParatext "false" @default.
• W4381197860 isRetracted "false" @default.
• W4381197860 workType "article" @default.